Royce & Associates LP Acquires 32,879 Shares of Apyx Medical Co. (NASDAQ:APYX)

Royce & Associates LP boosted its holdings in shares of Apyx Medical Co. (NASDAQ:APYX) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,615,369 shares of the company’s stock after acquiring an additional 32,879 shares during the quarter. Royce & Associates LP owned approximately 6.95% of Apyx Medical worth $4,132,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in APYX. Raymond James Financial Inc. bought a new position in Apyx Medical during the fourth quarter valued at approximately $134,000. Commonwealth Equity Services LLC raised its position in Apyx Medical by 3.0% during the fourth quarter. Commonwealth Equity Services LLC now owns 527,061 shares of the company’s stock valued at $833,000 after acquiring an additional 15,500 shares in the last quarter. Finally, Kingsview Wealth Management LLC raised its position in Apyx Medical by 8.7% during the fourth quarter. Kingsview Wealth Management LLC now owns 135,245 shares of the company’s stock valued at $214,000 after acquiring an additional 10,800 shares in the last quarter. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Price Performance

Shares of APYX opened at $1.09 on Thursday. The firm has a market cap of $41.03 million, a PE ratio of -1.31 and a beta of 1.18. The firm’s 50 day moving average price is $1.37 and its 200 day moving average price is $1.38. The company has a debt-to-equity ratio of 3.03, a quick ratio of 4.52 and a current ratio of 5.46. Apyx Medical Co. has a twelve month low of $0.93 and a twelve month high of $1.99.

Apyx Medical (NASDAQ:APYX) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. Apyx Medical had a negative net margin of 58.59% and a negative return on equity of 137.98%. The company had revenue of $14.22 million for the quarter, compared to analyst estimates of $13.39 million. As a group, research analysts expect that Apyx Medical Co. will post -0.68 EPS for the current fiscal year.

Apyx Medical Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.